annb0t
Top 20
KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.
Arcturus Therapeutics (NASDAQ: ARCT) is currently developing next generation mRNA vaccines. It has developed a COVID-19 vaccine candidate and has recently ...
>>> Read more: CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
Arcturus Therapeutics (NASDAQ: ARCT) is currently developing next generation mRNA vaccines. It has developed a COVID-19 vaccine candidate and has recently ...
>>> Read more: CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
